➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
Boehringer Ingelheim
Mallinckrodt
Dow
Medtronic

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

Patent: 8,999,289

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,999,289
Title:Treatment of protein degradation disorders
Abstract: The invention relates to methods of treating protein degradation disorders, such cellular proliferative disorders (e.g., cancer) and protein deposition disorders (e.g., neurodegenerative disorders). The invention provides methods and pharmaceutical compositions for treating these diseases using aggresome inhibitors or combinations of aggresome inhibitors and proteasome inhibitors. The invention further relates to methods and pharmaceutical compositions for treating multiple myeloma. New HDAC/TDAC inhibitors and aggresome inhibitors are also provided as well as synthetic methodologies for preparing these compounds.
Inventor(s): Anderson; Kenneth C. (Wellesley, MA), Bradner; James E. (Weston, MA), Greenberg; Edward Franklin (Cleveland, OH), Hideshima; Teru (Brookline, MA), Kwiatkowski; Nicholas Paul (Auburn, MA), Mazitschek; Ralph (Belmont, MA), Schreiber; Stuart L. (Boston, MA), Shaw; Jared (Davis, CA), Haggarty; Stephen J. (Gloucester, MA)
Assignee: President and Fellows of Harvard College (Cambridge, MA) Dana-Farber Cancer Institute, Inc. (Boston, MA)
Application Number:11/386,959
Patent Claims:see list of patent claims

Details for Patent 8,999,289

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial President and Fellows of Harvard College (Cambridge, MA) Dana-Farber Cancer Institute, Inc. (Boston, MA) 2025-03-22 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial President and Fellows of Harvard College (Cambridge, MA) Dana-Farber Cancer Institute, Inc. (Boston, MA) 2025-03-22 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 8,999,289

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
AstraZeneca
McKinsey
Medtronic
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.